What is Harvard Bioscience?
Harvard Bioscience, Inc. operates as a premier developer and manufacturer of specialized technologies that underpin fundamental advances in life science research. The company provides a comprehensive suite of products and services essential for pharmaceutical discovery, therapy development, and bio-production. With a global footprint spanning the United States, Europe, and China, the organization serves a diverse clientele ranging from elite academic institutions to the world's most prominent contract research organizations. By maintaining a hybrid sales model that integrates direct channels with strategic distribution networks, Harvard Bioscience ensures its instrumentation and services remain at the forefront of preclinical testing and laboratory innovation.
How much funding has Harvard Bioscience raised?
Harvard Bioscience has raised a total of $156.4M across 3 funding rounds:
Stock Offering
$51.4M
Debt
$65M
Debt
$40M
Stock Issuance/Offering (2000): $51.4M, investors not publicly disclosed
Debt (2020): $65M led by Citizens Bank
Debt (2025): $40M supported by BroadOak Capital Partners
Key Investors in Harvard Bioscience
BroadOak Capital Partners
A boutique financial institution specializing in direct investment and advisory services specifically for the life sciences and biopharma services sectors.
Citizens Bank
One of the nation's largest financial institutions, providing comprehensive commercial banking and debt financing solutions to large corporations and institutional clients.
Undisclosed Investor
An undisclosed participant in the funding round, contributing to the overall capital structure of the organization.
What's next for Harvard Bioscience?
With the successful procurement of this latest capital, Harvard Bioscience is well-positioned to optimize its business strategy and expand its market share in the life sciences tools sector. The focus will likely shift toward enhancing its portfolio of diagnostic and biopharma services, leveraging the expertise of its financial partners to navigate the evolving landscape of drug discovery. As the industry faces increasing pressure to streamline preclinical workflows, the company's ability to provide high-precision, scalable solutions will be a key driver of its future performance. Investors and stakeholders will be monitoring how this strategic investment is deployed to bolster R&D initiatives and strengthen the firm's competitive advantage in the global marketplace.
See full Harvard Bioscience company page
